INNOVADERM CRO IS NOW INDERO.

Exploring the Intersections: Dermatology and Rheumatology Insights

Indero

Indero

Team of Experts

Indero is proud to spotlight an insightful discussion featuring Dr. Juan Ovalles, Senior Director, Rheumatology, and Dr. Jasmina Jankicevic, Chief Medical and Scientific Officer. In this webinar, the two leaders unpack the growing convergence between dermatology and rheumatology, exploring how shared biological pathways can drive smarter, more efficient clinical development strategies.

As chronic inflammatory diseases continue to reveal overlapping mechanisms, understanding these intersections is becoming essential. Dr. Ovalles and Dr. Jankicevic examine the common immunological drivers, including TNF‑alpha, IL‑17, and IL‑23, and explain how they influence both therapeutic approaches and trial design across multiple indications.The conversation also highlights key distinctions between dermatologic and rheumatologic conditions; insights that are critical for crafting precise protocols, selecting meaningful endpoints, and tailoring patient‑centric strategies.

👇🔊 Listen to the full discussion to explore the evolving relationship between dermatology and rheumatology and gain a deeper understanding of the pathways shaping the next generation of clinical development.

Planning an upcoming rheumatology trial?

SHARE THIS POST

Subscribe to our Podcast.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.